Documents
Implementation of TRIPS and Access to Medicines for HIV after January 2016: Strategies and Options for Least Developed Countries
22 November 2011
This document seeks to analyse how LDCs have utilized the 2016 extension to facilitate the production and access to HIV and other medicines for their populations; discuss what can be done to maximize the opportunities provided by the current extensions; describe the potential implications of LDCs having to implement the TRIPS Agreement with respect to pharmaceuticals and test data protection; fill the gaps in the understanding of the process for further extension of the transition period for pharmaceutical products; and provide recommendations on how LDCs should proceed to seek further extensions.
Related
U=U can help end HIV stigma and discrimination. Here’s how

27 February 2025
Impact of community-led and community-based HIV service delivery beyond HIV: case studies from eastern and southern Africa
30 January 2025
Lost and link: Indonesian initiative to find people living with HIV who stopped their treatment

21 January 2025
Indicators and questions for monitoring progress on the 2021 Political Declaration on HIV and AIDS — Global AIDS Monitoring 2025
17 December 2024
UNAIDS data 2024
02 December 2024